Prognosis for patients with stage III melanoma and use of immunotherapy

Balch CM, et al.
Prognostic factors analysis of 17,600 melanoma patients: validation of the
American Joint Committee on Cancer melanoma staging system.
J Clin Oncol. 2001 Aug 15;19(16):3622-34.
PMID: 11504744
“Factors predicting melanoma-specific survival rates were analyzed using the Cox proportional hazards regression model. Follow-up survival data for 5 years or longer were available for 73% of the patients.” (from the abstract). Includes analysis of prognosis for stage III by tumor burden, ulceration, and nodal involvement.

Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA.
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005413. Review.
PMID: 17253556
Sytematic review of 18 (out of 28 identified) studies on the use of chemotherapy v. chemotherapy plus immunotherapy in the treatment of metastatic melanoma.
The Atzpodien and Danson studies were the only ones to include patients with brain metastases.
To see summary of results for each study, go to the Analyses Section. Clicking on the links under Outcome Title for each table will show statistics for each study regarding that outcome.


About Amy

Clinical Informationist at EUH Branch Library
This entry was posted in Prognosis and tagged . Bookmark the permalink.